Welcome Guest
Home » Reports » Cell Line Development Services Market, 2017-2027

Cell Line Development Services Market, 2017-2027

Published: Jul 26, 2017
Pages: 278
Product Code: RA10086
License Type :  (Learn More)

The growing pipeline of biological drugs has resulted in a continuous increase in the demand for different types of cell lines. More than 650 biologics have been approved till date, and over 1,500 are under clinical development. Additionally, the loss of patent exclusivity of several biologics in the coming years is likely to be followed by the entry of numerous biosimilars as many companies compete to grab a share of already established drug markets. The importance of cell lines in other areas, such as drug screening, gene functional studies, cell-based assay development, diagnostics and tissue engineering, has resulted in further increase in the demand for different types of cell lines. The rapid progression of biological drug candidates through various phases of development, coupled with the growing demand of cell lines for other applications, presents significant opportunities to cell line development service providers.

 

The market already has a wide array of well-established players, mid-sized companies and start-ups. Several industry players are contributing to the production of GMP and non-GMP grade cell lines that are obtained from mammalian, microbial, insect-derived, avian, marine, reptilian and other sources. Stakeholders have entered into multiple partnerships / collaborations in order to improve and scale-up production processes, and expand their capabilities. Considering the heightened activity in this domain, we believe the market is likely to evolve at a steady pace in the mid to long term, driven primarily by the increasing demand for cell lines, and advances in technology platforms and production methodologies.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The ‘Cell Line Development Services Market, 2017 - 2027’ report provides an extensive study of the rapidly growing market of cell lines. Cells obtained from mammalian and microbial sources are widely used for the development and manufacturing of biotherapeutic products, such as recombinant proteins, antibodies and vaccines. Mammalian cell lines, owing to their inherent high productivity and ability to produce complex biopharmaceuticals, are relatively more preferred. At the same time, microbial cell lines are also widely used due to their less complex nature, low cost and high versatility.

 

As mentioned earlier, in addition to the large number of biologics that are already available in market, many are under various stages of development. In fact, close to 50% of product candidates in the current development pipeline are in the preclinical stage. Moreover, a number of important biologics, such as Aransep®, Avastin®, Herceptin®, HUMIRA®, Neulasta® and REMICADE®, are approaching patent expiration, and several companies are already engaged in the development of biosimilars and biobetters. As of May 2017, five biosimilars in the US and 28 in Europe have been approved. In addition to the US and EU, several companies based in Asia are also focused on the development of biosimilars. These developments have led to an upward surge in the demand for highly-productive and stable cell lines. High yielding cell lines, capable of producing top quality biopharmaceuticals, help in significantly reducing development and manufacturing costs. Hence, several companies have designed and developed innovative systems / technologies / proprietary manufacturing processes in order to optimize manufacturing costs and production timelines of the overall cell line development process. In addition to development-related services, several cell line manufacturers provide other services related to cell lines as a part of their respective services portfolios; examples of these services include cell line characterization, cell banking, cell bank characterization, process development and commercialization of reagents / equipment. It is also important to highlight that some of these companies offer cGMP production of biologics and fill / finish of end products as well.

 

This study presents an in-depth analysis of companies that are actively involved in providing cell line development services. In addition to other elements, the study features:

  • A discussion on the database of cell line development service providers along with information on the location of their manufacturing facilities, distribution of cell lines based on the source from which they are obtained (mammalian, microbial, insect-derived, avian, marine and reptilian), type of cell lines (recombinant, hybridoma and primary cell lines), technology used for the production of cell lines, purpose of production (R&D, diagnostics, biomanufacturing and tissue engineering), and other associated services (cell line characterization, cell banking, cell bank characterization, process development, cGMP manufacturing of biologics, fill / finish of end products and commercialization of reagents / equipment).
  • A detailed analysis of the database presented as three schematic representations; a world map depicting the most active geographies in terms of the presence of cell line development facilities, a heat map representing the distribution of database companies on the basis of their location (continent-wise distribution), year of establishment and cell line development capabilities, and a logo landscape signifying the distribution of companies based on the number of employees and the source from which cell lines are obtained.
  • Elaborate profiles of key industry players that have proprietary technologies for the development of cell lines and offer cell line characterization, cell banking and cGMP production of biologics as part of their services portfolios; each profile features an overview of the company, its financial performance, information on cell line development services and proprietary technology, manufacturing facilities, expansions and collaborations, and a comprehensive future outlook.
  • Profiles of non-industry players (cell line repositories) that play an active role in the development of cell lines and offer affiliated services; each profile features an overview of the repository and a brief description about its cell line development services.
  • Potential future growth opportunities in the cell line development market, segmented by regions, source and grade of cell lines. For the purposes of this analysis, we took into consideration several parameters, such as the number of companies involved, price of cell lines depending upon whether they are characterized or uncharacterized, source of cell lines, and average annual cell line development projects undertaken by companies.

 

We have provided informed estimates of the size of the market in the short to mid-term and long term for the period 2017-2027. To account for the uncertainties associated with the development of cell lines and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market’s evolution. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The insights presented in this study were also influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Fan Chen (Vice President Bioprocessing, LakePharma), Michael Pointek(Managing Director, Artes Biotechnology), Nienke Smits (Business Development, Modiquest) and Oscar Hoogteijling (Business Development Manager, Bioceros).

 

 

Example Highlights

  1. Over 180 companies are actively providing cell line development services to several biopharmaceutical companies. Majority of these companies are located in North America (45%) and the EU (35%).
  2. Currently, more than 60% of cell line development service providers focus on the development and generation of mammalian cell lines, which are the most popular due to their ability to produce highly complex recombinant proteins, antibodies and vaccines that cannot be produced in other types of cell lines. Microbial cell lines are the second most important type; approximately 15% of the companies that we identified claim to provide microbial cell line development services.
  3. Cell lines are used for several purposes such as R&D studies, biomanufacturing, diagnostics and tissue engineering. Majority of the companies (over 45%) produce cell lines for R&D purposes; this is followed by companies producing cell lines for biomanufacturing purposes (over 40%). R&D activities include the production of cell based assays, reporter cell lines, ion channel expressing cell lines, drug discovery and screening, and production of non-GMP grade antibodies and other proteins. Examples of companies providing cell lines for R&D applications include (in alphabetical order) Abcam, Altogen Labs, Applied Biological Materials, ATGCell, Bhat Bio-Tech, BPS Bioscience, CreaCell, DiscoverX, Eurofins Scientific, Euroscreen, GeneCopoeia GVK Biosciences, InvivoGen, SB Drug Discovery, System Biosciences, Trend Pharma & Tech, Vectalys, WatsonBio Sciences. Similarly, biomanufacturing involves the production of different types of therapeutic products (monoclonal and polyclonal antibodies, recombinant proteins and vaccines) and biosimilars.Examples of companies producing cell lines for biomanufacturing applications include (in alphabetical order) AbbVie, Abzena, Batavia Biosciences, Biovian, Boehringer Ingelheim BioXcellence, CMC Biologics, Cobra Biologics, FUJIFILM Diosynth Biotechnologies, Inno Biologics, LFB Biomanufacturing, MassBiologics and Patheon.
  4. More than 20% of the database companies providing cell line development services also offer cell banking (stand-alone service) and approximately 15% provide cell line characterization services (stand-alone service) to their customers. Some other services included as a part of service portfolio are cGMP manufacturing of biologics, fill / finish and services related to reagents / equipments. Examples of companies offering some of the aforementioned services include (in alphabetical order) Celonic, EuBiologics, Fusion Antibodies, Goodwin Biotechnology, Lonza, Nanotherapeutics, ProBioGen, Rentschler Biotechnologie, Selexis and Syngene International.
  5. The heightened competition and growing demand for cell lines has resulted in the emergence of several novel and innovative technologies, lowering of manufacturing costs and production timelines. Examples of some companies that have developed proprietary technologies for production of cell lines include (in alphabetical order) Abzena (Composite CHO™ technology), ACROBiosystems (HEKMax® Stable Cell Line Technology), BioFactura (StableFast™ Biomanufacturing Platform), Batavia Biosciences (STEP® technology), Celltheon (SMART™ expression platform), Celonic (CHOvolution™ / SEFEX platform), Cevec Pharmaceuticals (CAP®GO platform) and Selexis (SUREtechnology Platform™).
  6. Stakeholders have extensively collaborated during the last few years for a variety of purposes, such as out / in licensing of technologies, development of cell lines for specific drug candidates and acquisition / development of manufacturing facilities. For instance, Progenics Pharmaceuticals (June 2016), Sanofi Biologics (February 2017) and Xencor (November 2016) collaborated with Selexis to gain access to Selexis’ CHO-M Cell Line™ technology and the SUREtechnology Platform. More recently, in February 2017, Lonza and Sanofi entered into a joint venture agreement to establish a large scale mammalian cell culture facility in Visp, Switzerland, for the production of monoclonal antibodies. Earlier, in September 2015, Abzena acquired PacificGMP with an aim to expand its cell line development services. PacificGMP was a provider of contract process development, and non-GMP and cGMP manufacturing services for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene and cell therapy products.
  7. We expect the cell line development services market to grow at an annualized rate of ~10% over the course of next decade; this growth will be driven by the robust pipeline of biologics, increasing number of approvals of biological drug candidates, growing adoption of biosimilars, introduction of advanced production technologies, capability and capacity expansions, and the establishment of new cell line generation facilities. As the market evolves, cell lines obtained from mammalian sources will continue to form a major portion of the overall cell line development services market (~80%). North America and EU, with ~40% and ~35% of the current market, respectively, are likely to remain the major manufacturing hubs in the coming decade.

 

 

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the cell line development services market over the coming decade.

 

Chapter 3 provides a general introduction to the various types of cell lines. It includes a detailed discussion on the sources, selection and maintenance conditions, key features, applications and limitations of currently available cell lines. The chapter also provides a brief description of cell line characterization and cell banking services.

 

Chapter 4 identifies the contract service providers that are actively involved in the development of cell lines. The chapter provides details on the cell line development capabilities of these organizations, geographic location of their facilities, information on the proprietary technology (if any) used by the company for cell line development, type of cell lines produced by the company (recombinant, hybridoma and primary) and applications of the cell lines (such as for R&D activities, biomanufacturing, diagnostics and tissue engineering). The chapter also provides the distribution of companies based on the other services that they offer; these include cell line characterization, cell bank characterization, cell banking, process development, cGMP manufacturing of biologics, fill / finish and commercialization of reagents / equipment.

 

Chapter 5 presents a detailed analysis of the cell line development services market landscape. It features a schematic representation on world map, highlighting the key geographical locations of cell line manufacturing facilities. Further, we have provided a heat map analysis representing the distribution of companies on the basis of their location, year of establishment and cell line development capabilities. The chapter also provides a logo landscape of companies based on their size (employee base) and source of cell lines produced.

 

Chapter 6 offers detailed profiles of contract cell line development service providers that have developed proprietary technology / technologies for the production of cell lines. Each profile provides an overview of the company, its financial performance, details on its proprietary technology / technologies, information on its cell line manufacturing capabilities, recent investments / expansions, relevant collaborations and partnerships that have been inked over the last few years, and a comprehensive future outlook.

 

Chapter 7 features profiles of additional players that offer cell line characterization, cell banking and cGMP production services, apart from cell line development services. However, the companies included in this chapter have not developed any proprietary technology / technologies for producing cell lines.

 

Chapter 8 features profiles of key non-industry players (cell line repositories) that are playing an active role in providing cell line development services. Each profile provides a brief overview of the organization and the services it offers.

 

Chapter 9 presents a 10-year sales forecast, highlighting the likely growth of the market for cell lines development services. We have segregated the broader opportunity by source of cell lines (mammalian, microbial, insect-derived and others), regions (North America, Europe, Asia and the Rest of the World) and grade of cell lines (GMP and non-GMP). Our predictions are backed by robust analysis of data procured from both secondary and primary sources. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic forecast scenarios.

 

Chapter 10 presents insights from a survey that we conducted for this study. The participants, who were primarily members of the Senior Management or CXO level representatives, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

 

Chapter 11 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and trends that are likely to determine the future evolution of this segment of the industry.

 

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. In this chapter, we have presented detailed transcripts of discussions held with Fan Chen (VP BioProcessing, LakePharma), Michael Pointek(Managing Director, Artes Biotechnology), Nienke Smits (Business Development, ModiQuest) and Oscar Hoogteijling (Business Development Manager, Bioceros).

 

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures in the report.

 

Chapter 14 is an appendix,which contains the list of companies and organizations that have been mentioned in the report.

 
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. Introduction to Cell Culture
3.2.1. Primary Cell Culture
3.2.2. Secondary Cell Culture
 
3.3. Types of Cell Lines
3.3.1. Recombinant Cell Lines
3.3.2. Hybridoma Cell Lines
3.3.3. Finite Cell Lines
3.3.4. Continuous Cell Lines
 
3.4. Sources of Cell Lines
3.4.1. Mammalian
3.4.2. Non-Mammalian
 
3.5. Selection of a Cell Line
3.6. Maintenance of Cell Lines
3.7. Key Features of a Cell Lines
3.8. Applications of Cell Lines
3.9. Key Concerns Associated with Cell Lines
3.10. Cell Line Characterization
3.11. Cell Banking
3.12. Need for Outsourcing Cell Line Related Operations
 
4. Market Overview
4.1. Chapter Overview
4.2. Cell Line Development Services Providers: Market Landscape
4.2.1. Distribution by Location of Manufacturing Facility
4.2.2. Distribution by Source of Cell Lines
4.2.3. Distribution by Type and Applications of Cell Lines
4.2.4. Distribution by Other Services Related to Cell Line Development
 
5. Competitive Landscape 
5.1. Chapter Overview
5.2. Regional Analysis
5.3. Heat Map Analysis
5.4. Analysis by Source of Cell Lines and Size of Company
 
6. Company Profiles of Key Players
6.1. Chapter Overview
6.2. Abzena
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Cell Line Development Services and Technology Platforms
6.2.4. Manufacturing Facilities
6.2.5. Recent Developments
6.2.5.1. Collaborations
6.2.5.2. Investments and Expansions
6.2.5.3. Acquisitions
6.2.6. Future Outlook
 
6.3. Batavia Biosciences
6.3.1. Company Overview
6.3.2. Cell Line Development Services and Technology Platforms
6.3.3. Manufacturing Facilities
6.3.4. Recent Developments
6.3.4.1. Collaborations
6.3.4.2. Investments and Expansions
6.3.5. Future Outlook
 
6.4. Celonic
6.4.1. Company Overview
6.4.2. Cell Line Development Services and Technology Platforms
6.4.3. Manufacturing Facilities
6.4.4. Recent Developments
6.4.4.1. Collaborations
6.4.4.2. Investments and Expansions
6.4.5. Future Outlook
 
6.5. CMC Biologics
6.5.1. Company Overview
6.5.2. Cell Line Development Services and Technology Platforms
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments
6.5.4.1. Collaborations
6.5.4.2. Investments and Expansions
6.5.4.3. Acquisitions
6.5.5. Future Outlook
 
6.6. Cobra Biologics
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Cell Line Development Services and Technology Platforms
6.6.4. Recent Developments
6.6.4.1. Collaborations
6.6.4.2. Investments and Expansions
6.6.5. Future Outlook
 
6.7. Hyprocell
6.7.1. Company Overview
6.7.2. Cell Line Development Services and Technology Platforms
6.7.3. Future Outlook
 
6.8. LFB Biomanufacturing
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Cell Line Development Services and Technology Platforms
6.8.4. Manufacturing Facilities
6.8.5. Recent Developments
6.8.5.1. Collaborations
6.8.5.2. Investments and Expansions
6.8.6. Future Outlook
 
6.9. Lonza
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Cell Line Development Services and Technology Platforms
6.9.4. Manufacturing Facilities
6.9.5. Recent Developments
6.9.5.1. Collaborations
6.9.5.2. Investments and Expansions
6.9.5.3. Acquisitions
6.9.6. Future Outlook
 
6.10. ProBioGen
6.10.1. Company Overview
6.10.2. Cell Line Development Services and Technology Platforms
6.10.3. Recent Developments
6.10.3.1. Collaborations
6.10.3.2. Investments and Expansions
6.10.4. Future Outlook
 
6.11. Selexis
6.11.1. Company Overview
6.11.2. Cell Line Development Services and Technology Platforms
6.11.3. Recent Developments
6.11.3.1. Collaborations
6.11.3.2. Investments and Expansions
6.11.4. Future Oulook
 
6.12. trenzyme
6.12.1. Company Overview
6.12.2. Cell Line Development Services and Technology Platforms
6.12.3. Recent Developments
6.12.3.1. Collaborations
6.12.4. Future Outlook
 
7. Company Profiles of Additional Players
7.1. Chapter Overview
7.2. Biovian
7.3. Charles River Laboratories
7.4. EuBiologics
7.5. Inno Biologics
7.6. Nanotherapeutics
7.7. Oxford Genetics
7.8. RD-Biotech
7.9. Syngene International
7.10. TPG Biologics
7.11. WuXi Biologics
 
8. Cell Line Repositories
8.1. Chapter Overview
8.2. American Type Culture Collection (ATCC)
8.2.1. Overview
8.2.2. Services Portfolio
 
8.3. Leibniz Institute DSMZ
8.3.1. Overview
8.3.2. Services Portfolio
 
8.4. European Collection of Authenticated Cell Cultures (ECACC)
8.4.1. Overview
8.4.2. Services Portfolio
 
8.5. Coriell Institute for Medical Research
8.5.1. Overview
8.5.1.1. Services Portfolio
 
9. Market Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Input Data Tables and Assumptions
9.4. Cell Line Development Services Market Outlook, 2017-2027
 
9.5. Distribution of Future Opportunity by Source of Cell Lines
9.5.1. Cell Line Development Services Market for Mammalian Cells, 2017-2027
9.5.2. Cell Line Development Services Market for Microbial Cells, 2017-2027
9.5.3. Cell Line Development Services Market for Insect Cells, 2017-2027
9.5.4. Cell Line Development Services Market for Other Cells, 2017-2027
 
9.6. Distribution of Future Opportunity by Geography
9.6.1. Cell Line Development Services Market in North America, 2017-2027
9.6.2. Cell Line Development Services Market in the EU, 2017-2027
9.6.3. Cell Line Development Services Market in Asia, 2017-2027
9.6.4. Cell Line Development Services Market in the Rest of the World, 2017-2027
 
9.7. Distribution of Future Opportunity by Grade of Cell Lines
9.7.1. Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027
9.7.2. Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027
 
10. Survey Analysis
10.1. Chapter Overview
10.1.1. Overview of Respondents
10.1.2. Seniority Level of Respondents
10.2. Type of Cell Lines
10.3. Source of Cell Lines
10.4. Applications of Cell Lines
10.5. Cell Line Characterization Services
10.6. Cell Banking Services
10.7. Biologics Manufacturing Services
10.8. Fill / Finish Services
 
11. Conclusion
11.1. Mammalian and Microbial Cell Lines Continue to be Preferred Over those Derived from Other Sources
11.2. Cell Line Characterization, Cell Banking, Process Development and Other Affiliated Services also form an Important Part of the Services Portfolio of Most of the Players
11.3. Innovative Technologies Developed to Optimize and Scale-up the Overall Cell Line Development Process are Emerging as Key Enablers to Future Growth
11.4. Companies Headquartered in the US and EU Dominate the Market Landscape; Asia is Emerging as an Alternative Destination for Provision of such Services
11.5. The Market Continues to Witness Significant Partnership Activity Indicating a Lucrative Future Potential
11.6. Escalating Biomanufacturing Activities and R&D Initiatives are Expected to Act as Key Drivers of the Market
11.7. Overall, the Cell Line Development Services Market is Poised to Grow at a Steady Pace in the Coming Decade
 
12. Interview Transcripts
12.1. Chapter Overview
12.2. Fan Chen, Vice President BioProcessing, LakePharma
12.3. Michael Pointek, Managing Director, ARTES Biotechnology
12.4. Nienke Smits, Business Development, ModiQuest
12.5. Oscar Hoogteijling, Business Development Manager, Bioceros
 
13. Appendix 1: Tabulated Data
 
14. Appendix 2: List of Companies and Organizations
 
 
Figure 3.1 Primary and Secondary Cell Culture
 
Figure 3.2 Recombinant Cell Line Development
 
Figure 3.3 Hybridoma Cell Line Development
 
Figure 3.4 Sources of Non-Mammalian Cell Lines
 
Figure 3.5 Applications of Cell Lines
 
Figure 3.6 Factors Affecting the Utility of Cell Lines
 
Figure 4.1 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Regions)
 
Figure 4.2 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Countries)
 
Figure 4.3 Cell Line Development Services Providers: Distribution by Source of Cell Lines
 
Figure 4.4 Cell Line Development Services Providers: Distribution by Type of Cell Lines
 
Figure 4.5 Cell Line Development Services Providers: Distribution by Applications of Cell Lines
 
Figure 4.6 Cell Line Development Services Providers: Distribution by Other Related Services
 
Figure 5.1 Regional Analysis: Distribution by Location of Manufacturing Facility
 
Figure 5.2 Heat Map Analysis: Distribution by Location of Manufacturing Facility and Year of Establishment
 
Figure 5.3 Cell Line Development Services Providers (North America): Distribution by Source of Cell Lines and Size of Company
 
Figure 5.4 Cell Line Development Services Providers (EU): Distribution by Source of Cell Lines and Size of Company
 
Figure 5.5 Cell Line Development Services Providers (Asia): Distribution by Source of Cell Lines and Size of Company
 
Figure 6.1 Abzena: Revenues, FY 2014-FY H1 2017 (EUR Million)
 
Figure 6.2 Abzena: Revenues by Business Divisions, FY 2015-FY 2016 (EUR Million)
 
Figure 6.3 Celonic: CHOvolution Technology
 
Figure 6.4 LFB Group: Revenues, FY 2012-FY 2016 (EUR Million)
 
Figure 6.5 LFB Group: Revenues by Therapeutic Areas and Services, 2016 (EUR Million)
 
Figure 6.6 LFB Biomanufacturing: Cell Line Development Process
 
Figure 6.7 Lonza: Custom Contract Manufacturing Services
 
Figure 6.8 Lonza: Revenues, FY 2012-FY 2016 (CHF Million)
 
Figure 6.9 GS Gene Expression System: Working Principle
 
Figure 6.10 Selexis: Cell Line Development Process
 
Figure 6.11 trenzyme: Cell Line Development Process
 
Figure 8.1 ATCC: Services Portfolio
 
Figure 8.2 Leibniz Institute DSMZ: Biological Material Collection
 
Figure 8.3 ECACC: Biological Material Collection
 
Figure 8.4 ECACC: Services Portfolio
 
Figure 8.5 Coriell Institute of Medical Research: Operating Segments
 
Figure 8.6 Coriell Institute for Medical Research: Services Portfolio
 
Figure 9.1 Cell Line Development Services Market, 2017-2027 (USD Billion)
 
Figure 9.2 Cell Line Development Services Market, 2017 and 2027: Distribution by Source of Cell Lines (USD Million) 
 
Figure 9.3 Cell Line Development Services Market for Mammalian Cells, 2017-2027 (USD Billion)
 
Figure 9.4 Cell Line Development Services Market for Microbial Cells, 2017-2027 (USD Million)
 
Figure 9.5 Cell Line Development Services Market for Insect Cells, 2017-2027 (USD Million)
 
Figure 9.6 Cell Line Development Services Market for Other Cells, 2017-2027 (USD Million)
 
Figure 9.7 Cell Line Development Services Market, 2017 and 2027: Distribution by Regions (USD Million)
 
Figure 9.8 Cell Line Development Services Market in North America, 2017-2027 (USD Million)
 
Figure 9.9 Cell Line Development Services Market in the EU, 2017-2027 (USD Million)
 
Figure 9.10 Cell Line Development Services Market in Asia, 2017-2027 (USD Million)
 
Figure 9.11 Cell Line Development Services Market in the Rest of the World, 2017-2027 (USD Million)
 
Figure 9.12 Cell Line Development Services Market, 2017 and 2027: Distribution by Grade of Cell Lines (USD Million)
 
Figure 9.13 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027 (USD Billion)
 
Figure 9.14 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027 (USD Million)
 
Figure 10.1 Survey Analysis: Distribution by Location of Organization
 
Figure 10.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
 
Figure 10.3 Survey Analysis: Distribution by Seniority Level of Respondents
 
Figure 10.4 Survey Analysis: Distribution by Types of Cell Lines
 
Figure 10.5 Survey Analysis: Distribution by Source of Cell Lines
 
Figure 10.6 Survey Analysis: Distribution by Applications of Cell Lines
 
Figure 10.7 Survey Analysis: Cell Line Characterization Services
 
Figure 10.8 Survey Analysis: Cell Banking Services
 
Figure 10.9 Survey Analysis: Biologics Manufacturing Services
 
Figure 10.10 Survey Analysis: Fill / Finish Services
 
Figure 11.1 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Source of Cell Lines
 
Figure 11.2 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Regions
 
Figure 11.3 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Grade of Cell Lines
 
 
Table 3.1 Comparison of Properties of Finite and Continuous Cell line
 
Table 3.2 Human Cell Lines and Therapeutic Protein Products
 
Table 3.3 Cell Lines and Viral Vaccine Products
 
Table 4.1 Cell Line Development Services Providers: List of Companies
 
Table 4.2 Cell Line Development Services Providers: Distribution by Source of Cell Lines
 
Table 4.3 Cell Line Development Services Providers: Distribution by Type and Application of Cell Lines
 
Table 4.4 Cell Line Development Services Providers: Distribution by Other Related Services
 
Table 6.1 CMC Biologics: Mammalian and Microbial cGMP Manufacturing Capabilities
 
Table 9.1 Input Data and Assumptions: Distribution of Cell Line Development Services Providers by Size of the Company and Grade of Cell Lines
 
Table 9.2 Input Data and Assumptions: Distribution of Price of Cell Lines by Source and Grade of Cell Lines
 
Table 9.3 Input Data and Assumptions: Distribution of Number of Projects Undertaken by Size of Company
 
Table 9.4 Input Data and Assumptions: Distribution of Source of Cell Lines by Percentage of Biopharmaceuticals Produced
 
Table 10.1 Survey Responses: Overview of the Respondents
 
Table 10.2 Survey Responses: Seniority Level of Respondents
 
Table 10.3 Survey Responses: Types of Cell Lines
 
Table 10.4 Survey Responses: Source of Cell Lines
 
Table 10.5 Survey Responses: Applications of Cell Lines
 
Table 10.6 Survey Responses: Cell Line Characterization Services
 
Table 10.7 Survey Responses: Cell Banking Services
 
Table 10.8 Survey Responses: Biologics Manufacturing Services
 
Table 10.9 Survey Responses: Fill / Finish Services
 
Table 13.1 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Regions)
 
Table 13.2 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Countries)
 
Table 13.3 Cell Line Development Services Providers: Distribution by Source of Cell Lines
 
Table 13.4 Cell Line Development Services Providers: Distribution by Type of Cell Lines
 
Table 13.5 Cell Line Development Services Providers: Distribution by Applications of Cell Lines
 
Table 13.6 Cell Line Development Services Providers: Distribution by Other Related Services
 
Table 13.7 Abzena: Revenues, FY 2014-FY H1 2017 (EUR Million)
 
Table 13.8 Abzena: Revenues by Business Divisions, FY 2015-2016 (EUR Million)
 
Table 13.9 LFB Group: Revenues, FY 2012-FY 2016 (EUR Million)
 
Table 13.10 LFB Group: Revenues by Therapeutic Areas and Services, 2016 (EUR Million)
 
Table 13.11 Lonza: Revenues, FY 2012-FY 2016 (CHF Million)
 
Table 13.12 Cell Line Development Services Market, 2017-2027: Base Scenario (USD Billion)
 
Table 13.13 Cell Line Development Services Market, 2017-2027: Conservative Scenario (USD Billion)
 
Table 13.14 Cell Line Development Services Market, 2017-2027: Optimistic Scenario (USD Billion)
 
Table 13.15 Cell Line Development Services Market, 2017 and 2027: Distribution by Source of Cell Lines (USD Million)
 
Table 13.16 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Base Scenario (USD Billion)
 
Table 13.17 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Conservative Scenario (USD Billion)
 
Table 13.18 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Optimistic Scenario (USD Billion)
 
Table 13.19 Cell Line Development Services Market for Microbial Cells, 2017-2027: Base Scenario (USD Million)
 
Table 13.20 Cell Line Development Services Market for Microbial Cells, 2017-2027: Conservative Scenario (USD Million)
 
Table 13.21 Cell Line Development Services Market for Microbial Cells, 2017-2027: Optimistic Scenario (USD Million)
 
Table 13.22 Cell Line Development Services Market for Insect Cells, 2017-2027: Base Scenario (USD Million)
 
Table 13.23 Cell Line Development Services Market for Insect Cells, 2017-2027: Conservative Scenario (USD Million)
 
Table 13.24 Cell Line Development Services Market for Insect Cells, 2017-2027: Optimistic Scenario (USD Million)
 
Table 13.25 Cell Line Development Services Market for Other Cells, 2017-2027: Base Scenario (USD Million)
 
Table 13.26 Cell Line Development Services Market for Other Cells, 2017-2027: Conservative Scenario (USD Million)
 
Table 13.27 Cell Line Development Services Market for Other Cells, 2017-2027: Optimistic Scenario (USD Million)
 
Table 13.28 Cell Line Development Services Market, 2017 and 2027: Distribution by Regions (USD Million)
 
Table 13.29 Cell Line Development Services Market in North America, 2017-2027: Base Scenario (USD Million)
 
Table 13.30 Cell Line Development Services Market in North America, 2017-2027: Conservative Scenario (USD Million)
 
Table 13.31 Cell Line Development Services Market in North America, 2017-2027: Optimistic Scenario (USD Million)
 
Table 13.32 Cell Line Development Services Market in the EU, 2017-2027: Base Scenario (USD Million)
 
Table 13.33 Cell Line Development Services Market in the EU, 2017-2027: Conservative Scenario (USD Million)
 
Table 13.34 Cell Line Development Services Market in the EU, 2017-2027: Optimistic Scenario (USD Million)
 
Table 13.35 Cell Line Development Services Market in Asia, 2017-2027: Base Scenario (USD Million)
 
Table 13.36 Cell Line Development Services Market in Asia, 2017-2027: Conservative Scenario (USD Million)
 
Table 13.37 Cell Line Development Services Market in Asia, 2017-2027: Optimistic Scenario (USD Million)
 
Table 13.38 Cell Line Development Services Market in the Rest of the World, 2017-2027: Base Scenario (USD Million)
 
Table 13.39 Cell Line Development Services Market in the Rest of the World, 2017-2027: Conservative Scenario (USD Million)
 
Table 13.40 Cell Line Development Services Market in the Rest of the World, 2017-2027: Optimistic Scenario (USD Million)
 
Table 13.41 Cell Line Development Services Market, 2017 and 2027: Distribution by Grade of Cell Lines (USD Million)
 
Table 13.42 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Base Scenario (USD Billion)
 
Table 13.43 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Conservative Scenario (USD Billion)
 
Table 13.44 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Optimistic Scenario (USD Billion)
 
Table 13.45 Cell Line Development Services Market for Non-GMP Cell Lines, 2017-2027: Base Scenario (USD Million)
 
Table 13.46 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027: Conservative Scenario (USD Million)
 
Table 13.47 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027: Optimistic Scenario (USD Million)
 
Table 13.48 Survey Analysis: Distribution by Location of Organization
 
Table 13.49 Survey Analysis: Distribution by Location of Manufacturing Facilities
 
Table 13.50 Survey Analysis: Distribution by Seniority Level of Respondents
 
Table 13.51 Survey Analysis: Distribution by Type of Cell Lines
 
Table 13.52 Survey Analysis: Distribution by Source of Cell Lines
 
Table 13.53 Survey Analysis: Distribution by Applications of Cell Lines
 
Table 13.54 Survey Analysis: Cell Line Characterization Services
 
Table 13.55 Survey Analysis: Cell Banking Services
 
Table 13.56 Survey Analysis: Biologics Manufacturing Services
 
Table 13.57 Survey Analysis: Fill / Finish Services
 
Table 13.58 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Source of Cell Lines
 
Table 13.59 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Regions
 
Table 13.60 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Grade of Cell Lines
 

 

The following companies and organizations have been mentioned in the report.

1          Abbott Nutrition

2          AbbVie

3          Abcam

4          ABclonal

5          Abeomics

6          Abgenex

7          ABLogiX

8          Abnova

9          Abzena

10        Acambis

11        Accurus Biosciences

12        ACROBiosystems

13        ACYTE Biotech

14        AdAlta

15        ADIENNE Pharma & Biotech

16        Agenus

17        Agilux Laboratories

18        Alexion

19        Algeta

20        Allele Biotechnology and Pharmaceuticals

21        Alligator Bioscience

22        Altogen Labs

23        America Pharma Source

24        American Type Culture Collection (ATCC)

25        Amgen

26        AMPO Biotechnology

27        AMS Biotechnology (AMSBIO)

28        Analytical Biological Services

29        Antitope

30        Applied Biological Materials

31        Aragen Bioscience

32        Areta International

33        arGEN-X

34        Aristi Biotech

35        ARTES Biotechnology

36        Asahi Glass Company (AGC)

37        AscentGene

38        ASLAN Pharmaceuticals

39        ATGCell

40        ATUM

41        AutekBio

42        Avid Bioservices

43        Babraham Research Campus

44        Batavia Biosciences

45        Baxter

46        Baylor Institute for Immunology Research (BIIR)

47        Bex

48        Bhat Bio-Tech

49        Bilthoven Biologicals

50        Bio Farma Indonesia

51        BioAzure Technologies

52        Bioceros (member of Polpharma Biologics)

53        Biocon

54        BioFactura

55        Bioingenium

56        BioInvenu

57        BioLab Innovative Research Technologies (BLIRT)

58        Biomet

59        Bionova Scientific

60        BioPharmaceuticals Australia

61        Biosettia

62        Biotie Therapies

63        Biovian

64        BioWa

65        Blue Stream Laboratories

66        Boehringer Ingelheim BioXcellence

67        Boston Mountain Biotech

68        BPS Bioscience

69        Bristol-Myers Squibb

70        C&M Biolabs

71        California Department of Public Health Food and Drug

72        California Institute for Regenerative Medicine

73        Capital Biosciences

74        Cell Essentials

75        CellaGenics

76        CellBank Australia

77        Cellomics Technology

78        Cellon

79        Celltheon

80        Cellutron

81        Celonic

82        Celplor

83        Celther Polska

84        Cerbios-Pharma

85        Ceva Santé Animale (Ceva)

86        Cevec Pharmaceuticals

87        Charles River Laboratories

88        CLS Cell Lines Service

89        CMC Biologics

90        Cobra Biologics

91        Columbia University

92        Commissariat général à l’égalité des territoires (CGET)

93        Complix

94        Cook Pharmica

95        Coriell Institute for Medical Research

96        Corning

97        CreaCell

98        Creative Biogene

99        Creative Biolabs

100      Creative BioMart

101      Crown Bioscience

102      Crucell (Johnson & Johnson)

103      Curaxys

104      Cytovance Biologics

105      Dainippon Sumito Pharma

106      DC3 Therapeutics

107      Delphi Genetics

108      DiscoverX

109      Dundee Cell Products

110      Eden Biodesign

111      EirGenix

112      Elabscience Biotechnology

113      EMD Serono

114      Emergent BioSolutions

115      EMP Genetech

116      EpiGex

117      Eton Bioscience

118      EuBiologics

119      Eugenom

120      Eurofins Scientific Scientific

121      European Collection of Authenticated Cell Cultures (ECACC)

122      European Equity Partners

123      Euroscreen

124      Evercyte

125      Evotec

126      ExcellGene

127      ExonBIO

128      ExpreS2ion Biotechnologies

129      FairJourney Biologics (FJB)

130      Faron Pharmaceuticals

131      Finnish Bioindustries (FIB) 

132      Finnish Fair Foundation

133      FivePrime Therapeutics

134   France Research North & South AIDS-HIV Hepatitis ANRS (National Health Agency for Research on AIDS and Hepatitis)

135      FUJIFILM Diosynth Biotechnologies

136      Fusion Antibodies

137      G&P Biosciences

138      Gala Biotech

139      GamaMabs Pharma

140      GATC Biotech

141      GE Capital

142      GE Equity International Mauritius

143      Gemini Biosciences

144      GeneBeyond

145      GeneCopoeia

146      GENENMED

147      Genlantis

148      GenScript

149      GlaxoSmithKline

150      Goodwin Biotechnology

151      GTP Technology

152      GVK Biosciences (GVK BIO)

153      Harvest Moon Pharmaceuticals

154      HealthTech and Medicines Knowledge Transfer Network

155      Heidelberg Pharma

156      Hera BioLabs

157      Horizon Discovery Group

158      Hyprocell

159      ibidi

160      IBI-Lorenzini

161      ICOS Corporation

162      ImmuNext

163      Immunostep

164      Inno Bio Ventures

165      Inno Biologics

166      Innoprot

167      Innoven Partenaires

168      InSCREENeX

169      Institut national de la santé et de la recherche médicale INSERM (National Institute of Health and Medical Research)

170      Institute of Biotechnology (Research Center Juelich)

171      InVivo BioTech Services (part of BRUKER Daltonics)

172      InvivoGen

173      Irvine Scientific

174      Jenner Institute, Oxford University

175      JHL Biotech

176      JRS Pharma

177      JSR Life Sciences

178      KAHR Medical

179      KBI Biopharma

180      Kodiak Sciences

181      Korea-Seoul Life Science Fund (KSLSF)

182      LakePharma

183      Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen

184      LFB Biomanufacturing

185      LFB Biotechnologies

186      Lonza

187      LPB Group

188      Lubris BioPharma

189      Mabion

190      MabPlex

191      Malaysian National Pharmaceutical Control Bureau (NPCB)

192      MassBiologics

193      MedImmune

194      Merck

195      Merica Technologies

196      Merus

197      MGC Pharmaceuticals

198      Minapharm Pharmaceuticals

199      ModiQuest

200      Monitor Clipper Partners

201      Multispan

202      Nanotherapeutics

203      National Biologics Facility

204      National Human Genome Research Institute

205      National Institute of Aging

206      National Institutes of Health (NIH)

207      New England Biolabs

208      Noble Life Sciences

209      NorClone Biotech Laboratories

210      Novartis

211      Novatein Biosciences

212      Novoprotein

213      Nunc

214      Oak BioSciences

215      Octoplus

216      OncoMed Pharmaceuticals

217      OncoSynergy

218      OneWorld Biotech

219      OSE Immnunotherapeutics

220      Oxford Expression Technologies

221      Oxford Genetics

222      Oxford Immunotec

223      Oxford Leadership

224      PacificGMP

225      Paragon Bioservices

226      PATH

227      Patheon

228      PBM Capital Group

229      Pfizer

230      Pharmaron

231      Pieris Pharmaceuticals

232      Polymun Scientific

233      PolyTherics

234      Precision Antibody

235      Premas Biotech

236      ProBioGen

237      Procter & Gamble

238      Profacgen

239      Progenics Pharmaceuticals

240      Promosome

241      ProNovus Biosciences

242      Protein Sciences

243      Protein Technologies

244      ProteoCell

245      PX'Therapeutics

246      RD-Biotech

247      Recopharma

248      Rentschler Biotechnologie

249      RIKEN BioResource Center

250      Roche

251      Rockland Immunochemicals

252      Rodon Biologics

253      RuiYi

254      SAL Scientific

255      Sanofi Biologics

256      Sanofi Pasteur

257      Sartorius Stedim Biotech (SSB)

258      Sartorius Stedim Cellca

259      SB Drug Discovery

260      SB Protein Expression

261      Selexis

262      Senior Housing Properties Trust

263      Serum Institute of India

264      Shanghai Genomics

265      Shanghai Henlius Biotech

266      Shanghai Medicilon

267      Sheffield University

268      Sigma Aldrich

269      Signosis

270      SinoBiological

271      Slovay Pharmaceuticals

272      Sorrento Therapeutics

273      Speed BioSystems

274      STC Biologics

275      Sundia MediTech

276      Sunomix Biosciences

277      Swedish Orphan Biovitrium

278      Syd Labs

279      Symphogen

280      Syngene International

281      System Biosciences

282      TaiMed Biologics

283      Tanvex BioPharma

284      TCG Lifesciences

285      TeneoBio

286      Terumo

287      Teva Pharmachemie

288      Texcell

289      TG Therapeutics

290      The Antibody Lab

291      The Chemistry Research Soluton (TCRS)

292      The Global Health Investment Fund I (GHIF)

293      The Helmholtz Protein Sample Production Facility (PSPF)

294      Therapure Biopharma 

295      Thermo Fisher Scientific

296      Tizona Therapeutics

297      TPG Biologics

298      TransViragen

299      Trend Pharma & Tech

300      Trenzyme

301      Triangle Research Labs (TRL)

302      TwinHelix

303      UCL Institute of Ophthalmology

304      UGA Biopharma

305      United BioLabs

306      University College London (UCL)

307      University of Franche Comté

308      University of Oxford

309      UvA Holding

310      Valneva Austria

311      Vectalys

312      VxP Biologics

313      Warwick Effect Polymers

314      WatsonBio Sciences

315      White Oak Global Advisors

316      WIL Research

317      Wockhardt

318      WuXi AppTec

319      WuXi Biologics

320      WuXi PharmaTec

321      Xencor

322      XOMA Corporation

323      Zymeworks

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security